Evaluation: Based on all recent filings, financial statements, and news.
See full evaluationCurrent Price
as of Dec 03, 2024$12.12
P/E Ratio
2.14
Market Cap
$8.82B
Roivant Sciences Ltd. engages in the biopharmaceutical business, which engages in the development of transformative medicine. Its product portfolio includes Vtama, Batoclimab, Brepocitinib, Namilumab, and RVT-2001, which aims to treat psoriasis, atopic dermatitis, thyroid eye disease, and other illnesses. The company was founded by Vivek Ramaswamy on April 7, 2014 and is headquartered in London, the United Kingdom.
Overview
Trading Information
Company